India’s More Impactful And Transformative Discovery In Gene Therapy 2025 At This Time

India’s More Impactful And Transformative Discovery In Gene Therapy 2025 At This Time:

Dr. Jitendra Singh Showcases BRIC-inStem’s

Innovation in "Haemophilia Treatment".

Positions Biotechnology as a Key Driver of the Nation’s Future Economy

"More Than Science – It’s Strategic Nation-Building": Minister Jitendra Singh Highlights Biotechnology as Pillar of India’s Future Economy. 

From Research to Real-World Impact: Bengaluru’s BRIC-inStem Drives India’s Biotech Revolution with Advanced Gene Therapy and Regenerative Medicine

"Biotechnology: Building Our Nation": Minister Highlights Biotech’s Economic Impact.

From Labs to Reality: Bengaluru's BRIC-inStem Drives India’s Bio-Revolution with Gene Therapy.

Dr. Jitendra Singh, the Union Minister in charge of several science and technology departments, visited the BRIC-inStem facilities in Bengaluru. He reviewed ongoing clinical trials, such as the pioneering human gene therapy trial for Haemophilia, conducted with CMC Vellore. He described this trial as a significant moment in India’s scientific development and praised the institute’s role in healthcare advances.

During his visit, Dr. Singh highlighted how biotechnology will shape India’s future economic and health structures. "This involves more than just science; it’s integral to building our nation," he said, commending the Department of Biotechnology for its remarkable progress and newfound importance.

India’s biotechnology industry has experienced tremendous growth over the past decade, expanding 16 times to reach $165.7 billion by 2024, with a goal of $300 billion by 2030. This progress has been supported by new policies like the BIO-E3 Policy, which focuses on boosting the economy, creating jobs, and enhancing environmental efforts. Dr. Singh pointed out, “We’ve grown from just 50 biotech startups to over 10,000 today.”

Dr. Singh also acknowledged the impact of the Biotechnology Research and Innovation Council (BRIC), which united 14 different institutions. He praised innovations like the anti-viral mask developed during the COVID-19 pandemic and the 'Kisan Kavach' product designed to shield farmers from harmful pesticides.

A highlight of the visit was BRIC-inStem’s Biosafety Level III lab, essential for researching dangerous pathogens as part of India’s One Health Mission. The pandemic taught India the importance of being prepared, and Dr. Singh noted, "Facilities like this ensure we stay ready."

The Minister further lauded the Centre for Research Application and Training in Embryology (CReATE), dedicated to addressing birth defects and infertility. "Considering that about 3 to 4 percent of babies are born with defects, this center plays a vital role in improving health outcomes for mothers and newborns," he stated.

Dr. Singh called for increased collaboration between science and medical institutions. He urged BRIC-inStem to explore joint MD-PhD programs, deepen involvement with clinical research, and raise awareness about their work. "The valuable efforts here must reach nationwide—not for publicity, but because it’s essential for the country," he emphasized.

The Union Minister in charge of several science and technology departments emphasized that India’s future economy will be powered by biotechnology, with pioneering institutions like BRIC-inStem leading the charge. Quoting Mark Twain, he remarked, “The economy is too serious a matter to be left solely to economists.” He added, “Biotechnology has evolved beyond the lab—it is now a strategic pillar of India’s growth and global leadership.”